Ra Pharmaceuticals Inc - Company Profile
Powered by
All the data and insights you need on Ra Pharmaceuticals Inc in one report.
- Save hours of research time and resources with
our up-to-date Ra Pharmaceuticals Inc Strategy Report
- Understand Ra Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Ra Pharmaceuticals Inc (Ra Pharmaceuticals), a subsidiary of UCB SA is a clinical stage biopharmaceutical company that develops therapeutics for patients with rare diseases based on its Extreme Diversity technology platform. It has pipeline products in pre-clinical, Phase I and Phase II trials for CNS diseases, autoimmune and renal disorders. The company’s lead product candidate, Zilucoplan, is a self-administered subcutaneous (SC) injection for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG). The company has collaboration with other companies to carry out the pre-clinical programs for glomerulonephritis (C3GN), and dense deposit disease (DDD). Ra Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US.
Ra Pharmaceuticals Inc premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
Zilucoplan |
Oral Macrocyclic Peptide |
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward